معرفی
Weng-Onn Lui is a Professor in Experimental Oncology at Karolinska Institutet's Department of Oncology-Pathology. His research focuses on small RNA biology, particularly microRNAs' roles in cancer development, drug resistance, and viral oncogenesis. He leads the 'Small RNAs in cancer development' research group, part of the Medical Genetics division under Catharina Larsson's group.
Education: PhD in Medical Genetics (Karolinska Institutet, 2002), BSc in Applied Science (Tunku Abdul Rahman College, Malaysia, 1996). Postdoctoral training at Stanford University (2004-2008) under Andrew Fire, and earlier postdoc experience in Molecular Medicine at Karolinska (2002-2004). Previous academic roles include Associate Professor (2014-2024), Senior Lecturer (2016-2024), and Swedish Research Council fellowships (2008-2016).
Key research areas include molecular mechanisms of Merkel cell carcinoma (MCC), miRNA regulation in drug resistance (e.g., BRAF inhibitors, imatinib), and Dicer enzyme dysfunction in cancer. His work bridges in vitro and in vivo models to explore miRNA-driven tumor progression and therapy response.
Notable awards include AACR-Ortho Biotech Scholar awards (2003, 2005-2006), the Stanford Comprehensive Cancer Center Translational Research Award (2007), and Swedish Research Council fellowships. Current grants include funding from the Swedish Cancer Society and Karolinska Institutet.
Advisory roles: Supervised PhD students Hannah Björn Andtback (2022) and Yaije Yang (2021). Active collaborations include teams at Fudan University (China), U Mass Medical School (USA), and Ludwig-Maximilians-University Munich (Germany). His lab investigates viral-driven cancer pathways, miRNA biomarkers, and therapeutic resistance mechanisms.
Laboratory affiliations: Based at Karolinska University Hospital-Solna (BioClinicum J6:20) with cross-disciplinary ties to the Catharina Larsson group. Research outputs span over 100 peer-reviewed articles in journals like Autophagy, Cancer Research, and Developmental Cell.
